利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.028 秒)

    Single variable domain immunoglobulins that bind TGF-beta receptor II
    2.
    发明授权
    Single variable domain immunoglobulins that bind TGF-beta receptor II 有权
    结合TGF-β受体II的单可变结构域免疫球蛋白

    公开(公告)号：US09150651B2

    公开(公告)日：2015-10-06

    申请号：US13978228

    申请日：2012-01-04

    申请人： Andrew Beaton ,  Caroline Dimech ,  Peter Franz Ertl ,  Susannah Karen Ford ,  Ruth Mcadam

    发明人： Andrew Beaton ,  Caroline Dimech ,  Peter Franz Ertl ,  Susannah Karen Ford ,  Ruth Mcadam

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N1/00 ,  C12N15/09

    摘要： The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.

    摘要翻译： 本公开提供了抗TGFbetaRII免疫球蛋白单可变结构域。 适当地，根据本公开内容的抗TGFbetaRII免疫球蛋白单可变结构域是具有SEQ ID NO：1-28中任一项所述的具有多达5个氨基酸取代，缺失或添加的氨基酸序列的抗TGFbetaRII免疫球蛋白单可变结构域。 本公开进一步提供了用于治疗与TGFbeta信号传导相关疾病的合适的多肽和药物组合物，并适当地选自以下组中的疾病：组织纤维化，例如肺纤维化，包括特发性肺纤维化; 肝纤维化，包括肝硬化和慢性肝炎; 类风湿关节炎; 眼部疾病; 皮肤纤维化，包括皮肤瘢痕疙瘩; Dupuytren的挛缩 肾纤维化如肾炎和肾硬化; 伤口愈合; 疤痕减少 和血管病变，如再狭窄。

    SYNTHETIC GENE
    3.
    发明申请
    SYNTHETIC GENE 审中-公开
    合成基因

    公开(公告)号：US20090274726A1

    公开(公告)日：2009-11-05

    申请号：US12439880

    申请日：2007-09-03

    申请人： Sara Jane Brett ,  Michael Nail Burden ,  Peter Franz Ertl ,  Paul Andrew Hamblin ,  John Philip Tite

    发明人： Sara Jane Brett ,  Michael Nail Burden ,  Peter Franz Ertl ,  Paul Andrew Hamblin ,  John Philip Tite

    IPC分类号： A61K39/21 ,  C12N15/11 ,  C12N15/00 ,  A61K39/00 ,  A61K39/29 ,  C12Q1/68

    CPC分类号： C07K14/535

    摘要： The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist.

    摘要翻译： 本发明涉及合成基因，设计所述合成基因的方法及其在基因治疗中的用途以及改进的DNA疫苗接种。 新的合成基因和过程是密码子洗牌的，使得它们相对于编码相同蛋白质的天然存在的基因具有降低的同源性，而不改变基因的总体密码子使用频率。 具体地说，本发明涉及用于治疗或预防疾病的改进的多核苷酸和包括密码子混合的GM-CSF核酸序列的方法。 本发明的核酸疫苗可以包含编码密码子洗牌的GM-CSF的核苷酸序列，编码要产生免疫应答的抗原的核苷酸序列和toll样受体（TLR）激动剂的组合。

    Vaccine
    6.
    发明授权
    Vaccine 失效
    疫苗

    公开(公告)号：US07655235B2

    公开(公告)日：2010-02-02

    申请号：US10533734

    申请日：2003-11-03

    申请人： Peter Franz Ertl

    发明人： Peter Franz Ertl

    IPC分类号： A61K39/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/53 ,  C07K2319/00 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322

    摘要： The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.

    摘要翻译： 本发明涉及用于DNA疫苗接种的多核苷酸，其多核苷酸编码HIV外壳蛋白或片段或免疫原性衍生物，当在哺乳动物靶细胞中表达时，其与非异源启动子可操作地连接而非糖基化。 优选地，HIV包膜分子，例如gp120或gp140或gp160，缺少功能性分泌信号。 它可能与其他HIV蛋白融合，如Nef，Gag，RT或Tat。

    VACCINE COMPOSITION
    7.
    发明申请
    VACCINE COMPOSITION 审中-公开
    疫苗组合物

    公开(公告)号：US20090208515A1

    公开(公告)日：2009-08-20

    申请号：US11913952

    申请日：2006-05-10

    申请人： Peter Franz Ertl ,  John Philip Tite ,  Catherine Ann Van Wely

    发明人： Peter Franz Ertl ,  John Philip Tite ,  Catherine Ann Van Wely

    IPC分类号： A61K39/00 ,  C12N15/63 ,  C12N15/87 ,  C07K2/00

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C12N2710/10043 ,  C12N2740/16034 ,  C12N2799/022

    摘要： The present invention relates to virus vectors comprising oligonucleotides encoding HIV polypeptides, more particularly wherein the virus vector is an adenovirus. In particular, such adenoviruses are non-human primate adenoviruses such as simian adenoviruses, more particularly chimpanzee adenoviruses. In particular the invention relates to adenovirus vectors which comprise HIV polynucleotide sequences which encode multiple different HIV antigens, for example two or three or more HIV antigens. The invention further relates to methods of preparing the virus vectors, to the virus vectors produced by the methods and to the use of the vectors in medicine especially prophylactic or therapeutic vaccination.

    摘要翻译： 本发明涉及包含编码HIV多肽的寡核苷酸的病毒载体，更特别地，其中病毒载体是腺病毒。 特别地，这样的腺病毒是非人灵长类动物腺病毒，例如猿猴腺病毒，更特别是黑猩猩腺病毒。 特别地，本发明涉及包含编码多种不同HIV抗原（例如两种或三种或更多种HIV抗原）的HIV多核苷酸序列的腺病毒载体。 本发明还涉及制备病毒载体的方法，通过方法产生的病毒载体以及在药物中使用载体，特别是预防性或治疗性疫苗接种。